A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Trial Evaluating the Efficacy and Safety of SHR-1314 Injection in Adults With Active Psoriatic Arthritis
Latest Information Update: 13 Nov 2024
Price :
$35 *
At a glance
- Drugs Vunakizumab (Primary)
- Indications Psoriatic arthritis
- Focus Registrational; Therapeutic Use
- Sponsors Suzhou Suncadia Biopharmaceuticals
- 11 Nov 2024 Status changed from not yet recruiting to recruiting.
- 18 Oct 2024 New trial record